Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | FABP4 | P15090 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349645 | 0.89 | MAPT (0.63) | MAPTTP53PTGS2FABP4SMN1; SMN2 | |
| SCHEMBL4444972 | 0.85 | MAPT (0.53) | MAPTTP53PTGS2SMN1; SMN2KDM4E | |
| SCHEMBL20651456 | 0.82 | MEN1 (0.53) | MAPTTP53PTGS2PTGDRL3MBTL1 | |
| SCHEMBL20637924 | 0.82 | PTGDR (0.49) | MAPTTP53PTGS2FABP4PTGDR | |
| SCHEMBL20637881 | 0.82 | CLK4 (0.50) | MAPTTP53PTGS2SMN1; SMN2VNN1 | |
| SCHEMBL30668859 | 0.82 | PTGDR (0.49) | MAPTTP53PTGS2FABP4PTGDR | |
| SCHEMBL29880059 | 0.82 | CLK4 (0.50) | MAPTTP53PTGS2SMN1; SMN2VNN1 | |
| SCHEMBL2448005 | 0.76 | MAPT (0.52) | MAPTTP53PTGS2FABP4SMN1; SMN2 | |
| SCHEMBL28046979 | 0.76 | PTGS2 (0.52) | MAPTTP53PTGS2FABP4SMN1; SMN2 | |
| SCHEMBL23326666 | 0.75 | MAPT (0.60) | MAPTTP53PTGS2FABP4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-4358963-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022271679-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | MAPT 431/4885TP53 4152/4885PTGS2 3324/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | MAPT 3961/4885TP53 447/4885PTGS2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.